国产替罗非班对急性冠脉综合征行PCI术患者的临床疗效分析被引量：1

下载PDF

导出

摘要目的:对急性冠脉综合征行PCI术的患者,在抗血小板抗凝治疗基础上加用国产替罗非班(商品名欣维宁),观察疗效并行安全性评价,尤其对替罗非班使用剂量作初步探讨。方法:选择2006年1月～2007年6月30日入院并明确诊断为急性冠脉综合征的患者,符合入选条件的127例,根据术后替罗非班使用剂量,按照自愿原则分为全量组(替罗非班以0.1ug/kg.min维持静脉点滴)和半量组(替罗非班以0.05ug/kg.min维持静脉点滴),所有患者均正规使用肝素(包括低分子肝素)、盐酸氯吡格雷、阿司匹林。观察临床特征,PCI术情况,终点事件为住院期间主要心血管事件(MACE)。结果:两组临床基线基本相似,没有统计学差异(P>0.05)。PCI术中病变数,其中三支病变数全量组占40.26%,半量组占44.00%双支病变全量组占37.66%,半量组占30.00%;单支病变全量组占22.08%,半量组占26.00%,两组比较P>0.05,没有统计学差异。住院期间MACE,非致命性心梗全量组3.90%(3例),半量组4.00%(2例);死亡全量组1.3%(1例),半量组2.00%(1例);总MACE发生率,全量组33.77%(26例),半量组34.00%(17例),两组之间没有统计学差异。结论:国产替罗非班对接受经皮血管成形术后急性冠脉综合征的患者是安全有效的,使用半量不会增加心血管事件的发生率。

作者黄春艳买苏木

机构地区新疆医科大学第一附属医院心血管专科医院重症监护病房

出处《新疆医学》 2008年第4期10-13,共4页 Xinjiang Medical Journal

关键词急性冠脉综合征替罗非班血小板GpⅡb/Ⅲa受体拮抗剂临床分析

分类号 R541.4 [医药卫生—心血管疾病] R973.2 [医药卫生—药品]

引文网络
相关文献

参考文献10

1Platelet Receptor Inhibition in Ischemic Syndrome Management(PRISM) Study Investigators. Acomparison of aspirin plus tirofiban with aspirin plus heparinfor unstableangina. NEnglJMed, 1998,338:1498 - 1505.
2The PRISM- PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non- Q -wave myocardial infarction. N Engl J Med, 1998,338:1488 - 1497.
3The RESTORE Investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockage with tirofiban on adverse cardiac events in patienta with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997,96 : 1445 - 1453.
4Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The task force for percutancous coronary interventions of the European society of cardiology. Eur Heart J,2005,26 (8) :804 -847.
5Braunwald E, Autmn EM, Beasley JW, et al. ACC/ AHA 2002 guideline update for the management of patients infarction : a report of the Amercian college of cardiology/American heart association task force on practice guide lines committee on the management of patients with unstable angina. J Am Coil Cardiol, 2002,40 : 1366 - 1374.
6唐强,霍勇,陈明,李建平,洪涛,郭来敬,王智,张树和,曲华清.盐酸替罗非班对急性心肌梗死急诊经皮冠状动脉介入治疗中TIMI血流影响的临床研究[J].中国介入心脏病学杂志,2006,14(2):97-99. 被引量：86
7李芳,余素琴,王琳.替罗非班对急性冠状动脉综合征患者临床症状和心电图的影响[J].临床心血管病杂志,2004,20(8):466-467. 被引量：23
8Yalgimigli M, Percoco G, Barbieri D, et al, The additive value of tirofiban administered with the high - dose bolus in the prevention of ischemic complications during high - risk coronary angioplasty: the Advance Trial. Am Coll Cardiol, 2004,44 ( 1 ) : 14 - 19.
9Yang Teng - yao, Chang Shi - tai, Chung Chang - ming. Restoration of normal coronary flow with tirofiban by intracoronary administration for no - reflow phenomenon after Stent deployment. Int Heart J, 2005,46( 1 ) : 139 - 144.
10杨新春,徐立,王乐丰,葛永贵,王红石,丁枭伟,王文君,邹阳春,李惟铭,刘宇.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究[J].中国循环杂志,2006,21(1):4-7. 被引量：91

二级参考文献19

1Platelet receptor inhibition in ischemic syndrome management(PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heprin for unstable angina. N Engl J Med, 1998, 338:1498-1505.
2The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein Ⅱ b/Ⅲ a receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,338:1488-1497.
3The RESTORE Investigators. Effects of platelet glycoprotein Ⅱ b/Ⅲ a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997,96:1445- 1453.
4Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation, 2002,105 : 656-662.
5Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein Ⅱ b/Ⅲ a blockade with primary PTCA Organization and Randomized Trial ( RAPPORT ). Circulation, 1998,98 : 734-741.
6Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344:1895-1903.
7Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acuete myocardial infarction. N Eng J Med, 2002, 346 : 957-966.
8Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blockade on recovery flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infction. Circulation, 1998, 98 : 2695-2701.
9Petronioa AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Euro Heart Journal, 2003, 24: 67-76.
10The RESTORE Investigators. Effects of platelet glycoprotein Ⅱ b/Ⅲ a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96: 1445-1453.